Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern

Khaleeq , Sara and Sengupta, Nayanika and Kumar, Sahil and Patel, U R and Rajmani, Raju S and Reddy , Poorvi and Pandey , Suman and Singh, Randhir and Dutta, Somnath and Ringe, Rajesh P. and Varadarajan, Raghavan (2023) Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses, 15 (2).

Full text not available from this repository. (Request a copy)
Official URL: https://https://www.mdpi.com/1999-4915/15/2/346

Abstract

Rapid emergence of the SARS-CoV-2 variants has dampened the protective efficacy of existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine immunogenicity by presenting multiple copies of desired antigens in a repetitive manner which closely mimics natural infection. We have applied nanoparticle display combined with the SpyTag-SpyCatcher system to design encapsulin-mRBD, a nanoparticle vaccine displaying 180 copies of the monomeric SARS-CoV-2 spike receptor-binding domain (RBD). Here we show that encapsulin-mRBD is strongly antigenic and thermotolerant for long durations. After two immunizations, squalene-in-water emulsion (SWE)-adjuvanted encapsulin-mRBD in mice induces potent and comparable neutralizing antibody titers of 105 against wild-type (B.1), alpha, beta, and delta variants of concern. Sera also neutralizes the recent Omicron with appreciable neutralization titers, and significant neutralization is observed even after a single immunization.

Item Type: Article
Additional Information: The copyright of this article belongs to MDPI
Uncontrolled Keywords: BA.4/5; Omicron; SWE adjuvant; SpyCatcher; SpyTag; encapsulin; negative stain; thermotolerant.
Subjects: Q Science > QR Microbiology
Depositing User: Dr. K.P.S.Sengar
Date Deposited: 07 Jun 2023 10:49
Last Modified: 07 Jun 2023 10:49
URI: http://crdd.osdd.net/open/id/eprint/3088

Actions (login required)

View Item View Item